Presentation in Boston at 9th Microbiome Movement Drug Development Summit, 10-12 July 2024

Cambridge, UK – 9 July 2024: Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines called live biotherapeutic products (LBPs), announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Microbiotica is a leading company developing LBPs based on the gut microbiome. Its lead programs, MB097 for advanced melanoma and MB310 for ulcerative colitis, are on track to enter clinical studies this year. In preparation, to scale processes for the production of cGMP-compliant clinical trial batches, Microbiotica entered into a manufacturing contract with Biose Industrie, a world-leading CDMO for microbiome therapeutics.

Each of Microbiotica’s LBPs comprise defined consortia of multiple bacterial strains, identified using its precision microbiome discovery platform which analyses the gut microbiome composition of patients and identifies bacterial species associated with clinical response. Manufacturing processes are developed for each individual bacterium, resulting in the production of freeze-dried stable powders which are combined into bespoke capsules for oral dosing.

Microbiotica has established expertise in the isolation and culturing of novel bacteria from the human gut microbiome, which it has leveraged, together with GMP manufacturing partner Biose, in the development of robust GMP manufacturing processes to produce batches for their multi-strain LBPs. Biose has provided its knowledge and experience in the industrialisation of bacterial manufacturing processes to scale-up the growth of these therapeutic bacteria, preserving them in stable freeze-dried state. GMP manufacturing processes for both programs have been developed at Biose.

“Working in partnership with the Biose team, we are delighted to have successfully navigated the challenges of process development and scale-up of two LBPs in parallel. Manufacturing of biologics can be challenging at the best of times, but the development of multiple processes to be scaled up to cGMP standard poses significant challenges, and seamless open collaboration between our project teams has been essential to success,” said Adam Wilkinson, Vice President of Pre-Clinical Development at Microbiotica.

Tim Sharpington, Microbiotica’s CEO, added, “Adam and his team, together with the Biose team, have done an amazing job to ensure that we are ready to start both of our clinical trials in the second half of this year. These first-in-patient trials will be a major milestone for the company.”

Microbiotica has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.

Details of the presentation:

Event: 9th Microbiome Movement Drug Development Summit
Date: Thursday 11 July
Time: 09.00-09.30
Place: Boston, USA
Session: Bringing the Cutting-Edge from the Clinic: Redefining Standards in Disease Management
Title: “Microbiotica & Biose Industrie: Developing & Manufacturing Two multi-strain Live Biotherapeutic Products for Clinical Studies”
Speakers: Adam Wilkinson, Vice President of Pre-Clinical Development, Microbiotica, and Claire Derlot, Chief Business Officer, Biose Industrie

- ENDS -

About Microbiotica

Microbiotica is a private, clinic-ready, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programs in immuno-oncology and inflammatory bowel disease (IBD).

The Company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to enable precise identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.

Microbiotica is creating a novel pipeline of programs in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis), both of which have data read-outs in 2025.

• The company has a supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA® in evaluating MB097 in melanoma patients with primary resistance to anti-PD-1 immunotherapy.

• MB310 was developed in collaboration with the University of Adelaide.

Microbiotica also has a major partnership with Cancer Research UK and Cambridge University Hospitals in immuno-oncology.

Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK.

Microbiotica has raised £62M equity investment, including a £50 M Series B in 2022, with venture investors including British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The company has also received financial support from the US-based Crohn’s and Colitis Foundation.

For more information, please visit www.microbiotica.com, and follow us on LinkedIn.